Development of CKD secondary to chronic heart failure (CHF), known as cardiorenal syndrome type 2 (CRS2), clinically associates with organ failure and reduced survival. Heart and kidney damage in CRS2 results predominantly from chronic stimulation of G protein-coupled receptors (GPCRs), including adrenergic and endothelin (ET) receptors, after elevated neurohormonal signaling of the sympathetic nervous system and the downstream ET system, respectively. Although we and others have shown that chronic GPCR stimulation and the consequent upregulated interaction between the G-protein bg-subunit (Gbg), GPCR-kinase 2, and b-arrestin are central to various cardiovascular diseases, the role of such alterations in kidney diseases remains largely unknown. We investigated the possible salutary effect of renal GPCR-Gbg inhibition in CKD developed in a clinically relevant murine model of nonischemic hypertrophic CHF, transverse aortic constriction (TAC). By 12 weeks after TAC, mice developed CKD secondary to CHF associated with elevated renal GPCRGbg signaling and ET system expression. Notably, systemic pharmacologic Gbg inhibition by gallein, which we previously showed alleviates CHF in this model, attenuated these pathologic renal changes. To investigate a direct effect of gallein on the kidney, we used a bilateral ischemia-reperfusion AKI mouse model, in which gallein attenuated renal dysfunction, tissue damage, fibrosis, inflammation, and ET system activation. Furthermore, in vitro studies showed a key role for ET receptor-Gbg signaling in pathologic fibroblast activation. Overall, our data support a direct role for GPCR-Gbg in AKI and suggest GPCR-Gbg inhibition as a novel therapeutic approach for treating CRS2 and AKI.
Cardiorenal syndrome (CRS) is defined as the pathologic crosstalk between the heart and kidney; it is clinically associated with increased incidence of failure of either or both organs and reduced survival. Worsening renal function coexists with cardiac pathologies in heart failure (HF), where impaired renal function is a strong predictor of mortality in patients with advanced chronic heart failure (CHF) of both ischemic and nonischemic etiologies. 1, 2 CRS is classified into five types depending on the organ of the initial disease and the type of disease (acute or chronic). CRS2 is characterized as CHF that leads to the development of CKD. CRS2 animal models described in the literature mostly used combined cardiac ischemic injury and renal injury, which generally does not recapitulate clinical settings. Recently, deterioration in renal function and mild focal fibrosis were observed 16 weeks postischemic cardiac injury in a mouse myocardial infarction model. 3 Here, we sought to investigate the development of CKD in a nonischemic transverse aortic constriction (TAC) CHF mouse model, possibly identifying a clinically relevant mouse model of CRS2.
Elevated neurohormonal signaling of the sympathetic nervous system (SNS) and its downstream endothelin (ET) system play a driving force in kidney and heart damage in CRS. 1, 2, [4] [5] [6] Elevated SNS and ET exert their effects through adrenergic and ET receptors, respectively, which belong to the superfamily of G protein-coupled receptors (GPCRs). 1, 2, [4] [5] [6] Chronic agonist stimulation induces GPCR internalization and signal termination, mediated predominantly by the interaction between the G-protein bg-subunit (Gbg), the G proteincoupled receptor kinase 2 (GRK2), [7] [8] [9] and b-arrestin. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] This Gbg-GRK2-b-arrestin signaling pathway is pathologically upregulated in cardiovascular disease, [17] [18] [19] [20] [21] where we and others have shown that interdicting the Gbg-GRK2 interaction may be salutary in the onset and progression of HF. 10, [22] [23] [24] [25] However, the role of GPCR-Gbg signaling in kidney injury remains poorly understood.
Using the murine pressure overload TAC model of HF as well as a direct bilateral ischemia-reperfusion AKI model, we studied the role of GPCR-Gbg signaling in cardiorenal and renal pathology, respectively. We have recently shown that the novel small molecule Gbg inhibitor gallein attenuates pathologic Gbg-GRK2 signaling in the heart and the adrenal gland, thus attenuating HF progression and normalizing SNS overactivity. 22 Here, we study the role of GPCR-Gbg signaling in cardiorenal and renal pathology, thus exploring a possible novel target for CRS2 therapy.
Clinically, renal fibrosis, inflammation, and dysfunction directly worsen HF prognosis and significantly reduce survival. 1, 2, [4] [5] [6] Our study identifies the role of GPCR-Gbg signaling in renal pathologic changes in a murine model of nonischemic CHF as well as in a direct AKI model. Our data suggest GPCR-Gbg inhibition as a possible novel therapeutic approach to attenuate renal damage and dysfunction in CRS2 and AKI.
RESULTS

CHF Mice Develop CKD 12 Weeks Post-TAC
TAC is a nonischemic pressure overload model where mice start developing HF 4-6 weeks post-TAC. At 12 weeks post-TAC, when mice are suffering from end stage nonischemic CHF, we found elevated serum creatinine levels ( Figure 1E ) and increased kidney injury marker 1 (KIM-1) protein expression ( Figure 1F ), indicating renal dysfunction and tubular damage, respectively. Histologically, hematoxylin-eosin staining showed focal tubular damage presenting as dilated tubules with simplified epithelia and vacuolized tubules ( Figure 1 , A and B). Furthermore, there was increased inflammatory cell infiltration in glomerular and tubular regions as shown by hematoxylin-eosin ( Figure 1C ), CD45 immunofluorescence staining ( Figure 1D ), and CD45 protein expression ( Figure   1G ). Picrosirius red staining revealed elevated focal tubulointerstitial and perivascular fibrosis in the kidneys of TAC mice ( Figure 2A ). Western blotting of whole renal lysates showed elevated protein expression of profibrotic a-smooth muscle actin (a-SMA) ( Figure 2B ) and ET-1 ( Figure 2C ), which is indicative of pathologic fibroblast activation and fibrotic signaling.
Small Molecule Gbg Inhibition Attenuates Renal Dysfunction and Tubulointerstitial Damage in a TAC HF Mouse Model Our recent study 22 showed the cardioprotective effects of the small molecule Gbg inhibitor gallein administered after the development of HF in a TAC HF mouse model, where it reduced mortality, attenuated cardiac hypertrophy and dysfunction, and attenuated adrenal and plasma catecholamine levels. Here, we found that small molecule Gbg inhibition by gallein initiated 4 weeks post-TAC (after the development of HF) and continued until week 12 (late stages of CHF) attenuated renal dysfunction, tubulointerstitial remodeling, fibrosis, and inflammatory cell infiltration in CHF mice (Figures 1  and 2 ).
GPCR-Gbg-GRK2 Signaling Is Elevated in Kidneys of CHF Mice and Attenuated by Gallein
Prior reports from our group and others show that elevated GRK2 protein expression and membrane translocation are key aspects of HF progression. 8, 9, [22] [23] [24] GRK2 protein expression and membrane translocation are elevated in kidneys of CHF mice, indicating elevated GPCR-Gbg-GRK2 signaling. This elevated GRK2 expression was attenuated by gallein treatment (Figure 3, A and B) .
ET System Is Elevated in Kidneys of CHF Mice and Attenuated by Gallein
Recent reports show a key role for ET signaling in the pathogenesis of renal dysfunction. [26] [27] [28] [29] [30] ET-1 protein expression is elevated in kidneys of TAC mice ( Figure 2C The Small Molecule Gbg Inhibitor, Gallein, Attenuates Renal Dysfunction and Damage in AKI In a bilateral renal ischemia-reperfusion injury (IRI) model of AKI, gallein pretreatment attenuated the elevation in tissue levels of the tubular injury marker NGAL ( Figure 4C ) and serum creatinine ( Figure 4D ), indicating attenuated renal tubular damage and dysfunction post-IRI, respectively. Mice pretreated with gallein showed less tubular expansion, tubular epithelial damage, and pathologic cast formation as shown in hematoxylin-eosin-stained kidney sections ( Figure 4 , A and B). The protective effect of gallein was more pronounced in the renal cortex ( Figure 4A ). Expression of the inflammatory genes monocyte chemoattractant protein 1 (Ccl2) ( Figure 4E ) and IL-1b (Il1b) ( Figure 4F ) was elevated 24 hours post-IRI and attenuated by gallein pretreatment. Furthermore, gallein pretreatment attenuated tubular apoptosis but had no effect on proliferation 24 hours post-IRI as shown by terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling (TUNEL) staining ( Figure 5 , A and B) and Ki-67 immunofluorescence ( Figure 5 , C and D), respectively. Furthermore, gene expression of ET-1 (Edn1) ( Figure 6A ) and its receptor ET A (Ednra) ( Figure 6B ) was elevated in AKI and reduced by gallein pretreatment, indicating a role for Gbg signaling in pathologic ET system elevation in AKI. This was accompanied by elevated gene expression of GRK2 (Adrbk1) ( Figure 6C ) that was also attenuated by gallein pretreatment, indicating a key role for GPCR-Gbg-GRK2 signaling in AKI.
Small Molecule Gbg Inhibition Attenuates ET Receptor-Mediated Extracellular Signal-Regulated Kinase 1/2 MAPK Activation in Cultured Mouse Embryonic Fibroblasts A dose-response study showed that a 100 nM solution of ET-1 induced near-maximum extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in cultured mouse embryonic fibroblasts (MEFs) (Supplemental Figure 1A) . Furthermore, a time course study showed that maximum ERK1/2 phosphorylation is attained 15 minutes after ET-1 (100 nM) stimulation (D) Immunofluorescence staining (320) and (G) Western blotting analysis for CD45 expression show an increase in kidney inflammation in 12-weeks TAC CHF mice. These histopathologic findings were accompanied by (E) worsening renal function as indicated by the elevated serum creatinine in these mice and (F) renal tissue damage as indicated by the elevated protein expression of KIM-1. All of these pathologic changes are attenuated by gallein treatment. Vehicle or gallein (10 mg/kg per day intraperitoneally) treatment was initiated 4 weeks post-TAC and continued until 12 weeks. Gallein was gradually titrated up to a maximal dose of 10 mg/kg per day and administered by intraperitoneal injection. G, gallein; V, vehicle. **P,0.01 (n=5-7 per group); ****P,0.001 (n=5-7 per group).
(Supplemental Figure 1B) . Both gallein pretreatment and knockdown of GRK2 with siRNA attenuated ET-1-mediated ERK1/2 phosphorylation ( Figure 7 , A and C), indicating a role for Gbg-GRK2 signaling in ET-1-mediated ERK1/2 phosphorylation in MEF. Interestingly, b-arrestin1,2 knockout had no effect on ET-1-mediated ERK1/2 phosphorylation in MEF ( Figure 7B ). Finally, combined ET A and ET B antagonism (BQ-123, 10 mM and BQ-788, 10 mM, respectively) and MEK inhibition (U-0126, 10 mM) inhibited ET-1-mediated ERK1/2 phosphorylation in MEF ( Figure 7A ).
In Vitro, ET Receptor Gbg Signaling Mediates MEF Migration
In a transwell migration assay, ET-1 (100 nM) stimulated cell migration. Gallein (10 mM) pretreatment, GRK2 siRNA knockdown, and b-arrestin1,2 knockout all attenuated cell migration. This indicates a direct role for the Gbg-GRK2-b-arrestin pathway in ET-1-mediated MEF migration. Combined ET A and ET B antagonism (BQ-123 and BQ-788, 10 mM) and MEK inhibition (U-0126, 10 mM) also attenuated MEF migration (Figure 7 , D-G).
DISCUSSION
A CRS2 Model: Nonischemic TAC CHF Mice Develop CKD CRS2 is a pathologic disorder where chronic dysfunction in the heart induces CKD, which worsens prognosis and reduces survival. 1, 2, [4] [5] [6] This study shows that TAC CHF mice chronically develop CKD, suggesting a CRS2 model. To date, the majority of studies investigating cardiorenal pathophysiology use combined ischemic cardiac injury and renal injury, which do not simulate clinical disease progression. Recently, deterioration in renal function and mild focal fibrosis were observed 16 weeks postinjury in a mouse myocardial infarction model. 3 Here, we show the development of CKD with deteriorating renal function, tubulointerstitial remodeling, and inflammation in the chronic phase of a nonischemic CHF mouse model (TAC) without surgical induction of kidney injury. Of note, no AKI was detected 24 hours after TAC surgery, and mild renal histopathologic changes and inflammation are observed as early as 7 days post-TAC (Supplemental Figures 2-4 ).
GPCR-Gbg Signaling Plays a Key Role in Kidney Injury
CRS is considered a complex molecular and systemic interplay of neurohumoral activation that induces cardiac hypertrophy and both myocardial and renal fibrosis, leading to cardiac and renal dysfunction. Neurohormonal activation, particularly SNS overactivity, plays a key role in the pathologic crosstalk between the heart and the kidney in CRS. Importantly, SNS modulation by renal denervation was recently investigated as a novel therapeutic approach for HF. 31 The SNS signals through adrenergic receptors that belong to the GPCR superfamily. Agonist stimulation of the GPCR induces signaling largely through the Ga followed by receptor internalization and signal termination. This (320) shows elevated renal interstitial and perivascular fibrosis (red color) in mice 12 weeks post-TAC, which is attenuated by gallein treatment. Protein expression of (B) the profibrotic marker a-SMA and (C) the fibrotic mediator ET-1 is elevated in the kidneys of CHF mice and attenuated by gallein treatment. Vehicle or gallein (10 mg/kg per day intraperitoneally) treatment was initiated 4 weeks post-TAC and continued until 12 weeks. Gallein was gradually titrated up to a maximal dose of 10 mg/kg per day and administered by intraperitoneal injection. G, gallein; V, vehicle. *P,0.05 (n=4-7 per group); **P,0.01 (n=4-7 per group); ***P,0.001 (n=4-7 per group).
internalization occurs because of the recruitment and binding of GRK2 by the free Gbg to phosphorylate the agonistoccupied receptor. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The phosphorylated GPCR triggers the recruitment of b-arrestins that scaffold the receptor complex and initiate its internalization. Chronic agonist stimulation of the GPCR triggers pathologic GRK2 upregulation and Gbg-GRK2 overactivity, leading to persistent GPCR phosphorylation and uncoupling of the receptor from its G proteins and resulting in GPCR pathologic signaling. This has been reported in various pathologic conditions, including cardiovascular disease. [9] [10] [11] [12] [13] [14] [15] [16] However, the role of GPCR-Gbg signaling in kidney disease remains poorly understood. We and others have shown that interdicting GPCR-Gbg-GRK2 signaling provides protection in both the onset and the progression of HF. 10, [22] [23] [24] [25] Our recent work 22 showed that the small molecule Gbg inhibitor, gallein, attenuates HF progression by simultaneously inhibiting the pathologically upregulated GPCR-Gbg signaling in the heart and the adrenal glands. Mechanistically, gallein restores physiologic GPCR signaling in the heart and the adrenal gland and attenuates SNS overactivity by normalizing adrenal secretion of catecholamines into the circulation.
In this study, we report elevated GRK2 protein expression in kidneys of CHF mice, indicating elevated GPCR-Gbg-GRK2 signaling in these kidneys. Remarkably, systemic small molecule Gbg inhibition attenuated renal pathologic changes together with the elevated GRK2 expression, suggesting a role for GPCR-Gbg signaling in kidney injury in CRS2. Importantly, gallein has no direct effect on systemic BP (data not shown); thus, a direct hemodynamic effect of gallein on hypertension in CHF is excluded. However, because gallein is administered systemically, we cannot exclude its effects on normalized SNS activity, improved cardiac function and structure, and hypertension that may play a role in attenuated kidney injury. Thus, we confirmed a direct effect of gallein on kidney injury in an AKI mouse model. We here report, for the first time, elevated GRK2 gene expression in AKI in parallel with tubular damage and elevated inflammatory gene expression. Gbg inhibition by gallein attenuated the observed inflammation, tubular damage, and subsequent deterioration of renal function in AKI mice.
Renal ET System and Fibrosis in Kidney Injury
Elevated neurohormonal signaling of the SNS and its downstream ET system through adrenergic and ET receptors, respectively, plays a driving force in kidney and heart damage in CRS. 8, 27, [32] [33] [34] [35] Both adrenergic and ETreceptors belong to the GPCR superfamily and are widely expressed in both the heart and the kidney. 8 Numerous preclinical studies have implicated ET-1 in the pathogenesis of CKD 27, 28 as well as in renal tubulointerstitial damage and fibrosis. 29, 32, 36 Renal fibrosis directly impedes renal function 37 and worsens HF in CRS2. 35 GRK2-b-arrestin signaling, downstream of the GPCR, plays a key role in cell growth, motility, and fibrosis and activates downstream pathways, such as MAPK, that are involved in pathologic cell proliferation and fibrosis. [17] [18] [19] [20] [21] However, the role of Gbg signaling in these processes has not been investigated. We suggest that pathologically elevated renal GPCR-Gbg-GRK2 signaling, as indicated by the elevated renal GRK2 protein expression and membrane translocation, promotes renal inflammation and fibrosis, thus contributing to HF progression in CRS2. Mechanistically, simultaneous attenuation of SNS overactivity and renal GPCR-Gbg pathologic signaling by gallein both seem to play a major role in renal protection.
Renal ET-1 production is almost universally increased in kidney disease, 29, 36 and it is activated downstream of the SNS. 32 Evidence exists for renal ET-1 acting as an independent system that plays a major role in renal tissue damage and malfunction, where ET A signaling is believed to be the major mediator of pathologic ET effects and plays a major role in the progression to CKD. 26, 29, 30, 36, 38 Remarkably, our data show elevated renal ET system in the kidneys of CHF mice; this implies that the ET system plays an important role in kidney injury secondary to CHF. Furthermore, the elevated ET system gene expression as previously reported in AKI 30, 39 was attenuated by gallein, indicating a direct role for Gbg signaling in kidney injury in AKI. Our in vitro studies in cultured MEFs showed that ET receptor Gbg-GRK2 signaling plays a key role in ET-1-mediated fibroblast activation. Altogether, this indicates that GPCR-Gbg signaling plays a major role in kidney injury in CRS2 and AKI. All of these pathologic changes are attenuated by gallein pretreatment. Vehicle or gallein (10 mg/kg per day) was administered 2 days before and on the day of surgery. G, gallein; V, vehicle. *P,0.05 (n=5-7 per group); **P,0.01 (n=5-7 per group); ***P,0.001 (n=5-7 per group); ****P,0.001 (n=5-7 per group).
Gbg Plays a Role in ET Receptor-Mediated MAPK Activation and Cell Migration MAPK signaling in general and ERK1/2 MAPK signaling in particular play a key role in ET-1-induced cell growth and motility, 17, 18, 40 processes that are essential for fibroblast activation and fibrosis. 19 ET-1 signaling through ETreceptors plays a major role in fibrosis, where ET A -b-arrestin signaling mediates MAPK signaling that promotes proliferation and migration in several cell types. 17, 18, 40 ET B has been thought to be protective in kidney injury 27 ; however, a recent study showed that peptide targeting of the intracellular loop of ET B receptor attenuated its downstream ERK activation in vascular smooth muscle cells. 41 Using in vitro cultured MEFs, we showed a direct and upstream role of Gbg in ET-1-mediated fibroblast ERK1/2 MAPK activation and cell migration. siRNA GRK2 knockdown, MEK inhibition, and ET receptor antagonism also blocked ET-1-mediated ERK1/2 MAPK activation and cell migration. b-Arrestin1,2 knockout in MEFs attenuated cell migration but had no effect on MAPK ERK1/2 activation, which can be explained by the reported differential regulation of GPCR signaling by b-arrestins. 17, 42 These data show a direct and upstream effect of Gbg signaling on ET receptor-mediated MAPK ERK1/2 Figure 6 . Gallein attenuates elevated gene expression of ET system and GRK2 in AKI. Gene expression of (A) ET-1 (Edn1) and (B) its receptor ET A (Ednra) is elevated in AKI 24 hours after bilateral renal IRI and attenuated by gallein pretreatment. (C) Gene expression of GRK2 (Adrbk1) is elevated in AKI and attenuated by gallein pretreatment. Vehicle or gallein (10 mg/kg per day) was administered 2 days before and on the day of surgery. G, gallein; V, vehicle. *P,0.05 (n=5 per group). activation and cell migration. Altogether, this indicates that gallein plays a key role in attenuating fibrosis by directly attenuating fibroblast migration and MAPK ERK1/2 activation.
In summary, TAC, in its chronic phase, represents a CRS2 model, where CHF leads to CKD. SNS overactivity plays a major role in the pathologic cardiorenal crosstalk in CHF. This study provides a novel therapeutic approach that simultaneously targets cardiac and renal pathologic GPCR-Gbg signaling. Current therapies for patients with HF and coexisting renal morbidities target the elevated blood volume and pressure. However, targeting the underlying pathologies, including pathologic GPCR-Gbg signaling in both the heart and the kidney, represents a promising therapeutic approach for CRS. Furthermore, our study shows that GPCR-Gbg signaling plays a direct role in AKI and suggests a novel possible therapeutic approach for AKI.
CONCISE METHODS
Animal Experiments CHF Experiment
Ten-week-old C57/Bl6 wild-type male mice (The Jackson Laboratory, Bar Harbor, ME) were subjected to TAC surgeries and divided Fifteen minutes post-ET-1 stimulation, maximal ERK1/2 phosphorylation is observed, and this effect is inhibited by (A) the small molecule Gbg inhibitor (gallein; 10 mM) and (B) b-arrestin1,2 knockout (b-arr1,2-KO). (C) GRK2 knockdown by siRNA transfection (siRNA-GRK2) also inhibited ET-1-mediated ERK1/2 phosphorylation relative to the scrambled siRNA transfected group (siRNA-scrm). (D-G) Using the transwell migration assay, MEFs migration was studied 4 hours after incubation with ET-1 (100 nM) in the lower chamber. ET-1 promoted MEF migration, which was inhibited by the small molecule Gbg inhibitor (gallein, 10 mM), (D and E) b-arrestin1,2 knockout (Barr1,2-KO), and (F and G) siRNA-GRK2. D and F are representative images (310) of DAPI-stained nuclei (blue) of the MEFs that migrated through the membrane, and E and G are bar graphs showing quantitative analyses of the number of MEFs that migrated through the membrane. ET receptor combined antagonism (ET A antagonist BQ-123 and ET B antagonist BQ-788, 10 mM each) and MAPK inhibition (MEK inhibitor U-0126, 10 mM) blocked the effect of ET-1 on ERK1/2 phosphorylation and MEFs migration. Vehicle or drug treatment was performed before cells were seeded in the upper chamber; n=5 for the ERK1/2 phosphorylation experiment, and n=4 for the transwell migration assay. G, gallein; V, vehicle; WT, wild type. *P,0.05; **P,0.01; ****P,0.001. into two groups: TAC and vehicle (n=11) and TAC and gallein (n=10). Sham-operated animals (n=6) served as controls. All animal procedures were performed in accordance with the guidelines of the Department of Laboratory Animal Medicine and the University Committee on Animal Resources at Cincinnati Children's Hospital Medical Center.
Surgery. TAC was performed as previously described. 22, 44, 45 Briefly, animals were anesthetized with isoflurane, intubated, and ventilated. After thoracotomy, TAC was created by securely placing a ligature around the transverse aorta and a 27-gauge needle, causing complete occlusion of aorta. The needle was then removed, leaving a stenotic aorta.
Treatment. Mice received a once daily intraperitoneal injection of either vehicle or gallein (10 mg/kg per day). Daily treatment was initiated 4 weeks post-TAC in a dose escalation manner and continued until euthanasia. 22 
AKI Experiment
To induce AKI, we used a bilateral renal IRI mouse model 46 ; 10-week old C57/Bl6 wild-type male mice (The Jackson Laboratory) were subjected to bilateral IRI surgeries and divided into two groups: IRI and vehicle (n=7) and IRI and gallein (n=7). Sham-operated animals (n=7) served as controls. All animal procedures were performed in accordance with the guidelines of the Department of Laboratory Animal Medicine and the University Committee on Animal Resources at Cincinnati Children's Hospital Medical Center.
Surgery. Mice were anesthetized, and an atraumatic (ROBOZ) clip was applied onto the renal artery and vein to induce renal ischemia of both the right and left kidneys for 30 minutes. Successful ischemia was visually confirmed by a gradual uniform darkening of the kidney. Mouse body temperature was maintained at 37°C for the duration of ischemia. Then, the clips were removed, and mice were allowed to recover.
Treatment. Mice were pretreated with three doses (intraperitoneal injection) of gallein (10 mg/kg per day) or vehicle 2 days before and on the day of surgery. Bilateral 30-minute ischemia followed by reperfusion was performed, mice were euthanized 24 hours post-IRI, and blood and kidneys were collected.
Renal Morphology and Fibrosis
Kidneys were isolated and fixed in 10% formalin solution for 24 hours, and then, they were processed in paraffin blocks. Paraffin sections were used for histologic analyses. Hematoxylin-eosin staining was performed on renal sections to study renal morphology. To assess fibrosis, picrosirius red staining was performed on renal sections, where fibrotic tissue is stained red.
Serum Creatinine
Collected blood was allowed to coagulate and then, centrifuged, and serum was isolated and stored at 280°C until use. Serum creatinine was estimated using the Creatinine Assay Kit from Abcam, Inc. (Cambridge, MA) following the manufacturer's protocol.
Protein Analyses Protein Isolation and Fractionation
Isolated kidneys were homogenized in a hypotonic lysis buffer and fractionated into membrane and cytosolic fractions by differential centrifugation as previously described. 47 
Western Blotting
Western blotting for GRK2, ET-1, ET A , ET B , a-SMA, and NGAL using the total unfractionated lysate was performed with GAPDH as internal standard to determine levels of protein expression. Western blotting for GRK2, ET A , ET B (normalized to caveolin-2 [Cav2]) was performed using membrane fractions to determine their membrane expression. Western blotting for KIM-1 and CD45 (normalized to Cav2) was performed to quantify their protein expression; membrane fractions were used, because both KIM-1 and CD45 are membrane proteins. GRK2 antibody is rabbit IgG from Santa Cruz Biotechnology (Santa Cruz, CA). ET A antibody is sheep IgG from Abcam, Inc., and ET-1, ET B , a-SMA, NGAL, and KIM-1 antibodies are rabbit IgGs from Abcam, Inc. Cav2 antibody is rabbit IgGs from Cell Signaling Technology (Danvers, MA). Additionally, GAPDH antibody is mouse IgG from EMD Millipore, and CD45 antibody is goat IgG from R&D Systems (Minneapolis, MN). Visualization and quantification of target bands were carried out with the LI-COR Odyssey Scanner and software (LI-COR Biosciences, Lincoln, NE) using IRDye secondary antibodies.
Apoptosis
The effect of gallein on the rate of renal apoptosis was determined by TUNEL staining of renal sections using the TUNEL Apoptosis Detection Kit (EMD Millipore) per the manufacturer's instructions, and apoptotic nuclei were visualized using confocal microscopy.
Immunofluorescence Staining
After euthanasia, kidneys were promptly isolated, fixed in 10% formalin, embedded in paraffin, and sliced into 5-mm sections. After deparaffinization, rehydration, and antigen retrieval, sections were permeabilized, blocked, and incubated with Ki-67 (rabbit IgG; Abcam, Inc.) or CD45 primary antibodies (goat; R&D Systems) followed by Alexa Fluor 488-conjugated secondary antibody (Invitrogen, Carlsbad, CA). Nuclei were stained with DAPI.
Quantitative Real-Time PCR Gene Expression
Gene expression of the inflammatory genes IL-1b and CCL2 as well as GRK2, ET-1, and ET A was quantified by real-time PCR analysis and normalized to the 18S ribosomal subunit as an internal standard, which we have previously described. [48] [49] [50] [51] mRNA was isolated from heart tissue using the RNeasy Mini Kit (Qiagen, Germantown, MD) per the manufacturer's instructions.
In Vitro MEFs Experiments MEFs Culture and ET-1-Mediated ERK1/2 Phosphorylation Experiment
MEFs were cultured in high-glucose DMEM with 10% heat-inactivated FBS, 1% nonessential amino acids, and 1% antibiotic/antimycotic. When cells reached 50% confluency, they were starved in 0.5% FBS in the culture media described above for 48 hours. To assess the role of Gbg on ET-1-mediated ERK1/2 phosphorylation, cells were pretreated with gallein (10 mM), combined ET A and ET B antagonists (BQ-123 and BQ-788, respectively; 10 mM each), or the MEK inhibitor (U-0126; 10 mM) for 2 hours and then, stimulated with ET-1 (100 nM) for 15 minutes. To assess the role of GRK2 in ET-1-mediated ERK1/2 phosphorylation, GRK2 was knocked down using specific validated siRNAwith a control experiment using scrambled siRNA as described below. Finally, to assess the role of b-arrestin1,2 in ET-1-mediated ERK1/2 phosphorylation, b-arrestin1,2 knockout MEFs (isolated from b-arrestin1,2 knockout mice) were used. Cells were washed with ice-cold PBS and harvested in mammalian protein extraction buffer (Fisher Scientific, Waltham, MA) containing a protease/ phosphatase inhibitor cocktail. Western blotting for ERK1/2 (p44/42 MAPK) and its phosphorylated form (Thr202/Tyr204) was performed on whole-cell lysate. ERK1/2 antibody is mouse IgG from Cell Signaling Technology, and phosphorylated ERK1/2 antibodies are rabbit IgGs from Cell Signaling Technology.
We performed a time course study and a dose-response study to establish the experimental conditions (concentration and time) for ET-1 stimulation (Supplemental Figure 1) .
MEFs siRNA Experiment
To knockdown GRK2, we used a validated GRK2-siRNA (AM51334-id147) from Life Technologies (Carlsbad, CA). Cells were transfected using Lipofectamine RNAiMAX (Life Technologies) following the manufacturer's reverse transfection protocol and using 20 nM siRNA. Control scrambled siRNA (Life Technologies) was used as a control. A time course study confirming GRK2 knockdown (.80%) until 72 hours was performed (Supplemental Figure 5 ).
MEFs Transwell Migration Assay
MEFs were cultured to subconfluency, serum starved for 24 hours, trypsinized, and counted, and 10 4 cells in 100 ml serum-free DMEM were seeded onto the upper surfaces of transwell inserts (8-mm pores; Fisher Scientific). Transwells were placed into wells on a 24-well plate containing vehicle or ET-1 (100 nM; Sigma-Aldrich, St. Louis, MO) in 600 ml medium in the lower chambers. MEFs were left at 37°C in 5% CO 2 in humidified air for 4 hours, fixed, and permeabilized in 100% methanol, and nuclei were stained with DAPI. MEFs on the upper surface of the membrane were removed with a cotton swab, and membranes were removed and fixed to glass slides; the numbers of migrated cells on the lower surface of the membrane were counted (310 objective). To assess the role of ET receptor Gbg or ERK1/2 in ET-1-stimulated cell migration, MEFs were incubated with the Gbg inhibitor (gallein, 10 mM), combined ET A and ET B antagonists (BQ-123 and BQ-788, respectively; 10 mM), or the MEK inhibitor (U-0126, 10 mM) for 30 minutes before agonist addition and throughout the assay. To assess the role of GRK2 in ET-1-mediated cell migration, GRK2 was knocked down using specific validated siRNA with a control experiment using scrambled siRNA as described above. Finally, to assess the role of b-arrestin1,2 in ET-1-mediated cell migration, b-arrestin1,2 knockout MEFs (isolated from b-arrestin1,2 knockout mice) were used.
Statistical Analyses
Multiple responses of various physiologic and biochemical assays were analyzed using one-way or repeated measures ANOVA. Post hoc analysis (Bonferroni correction) was performed if statistical significance (P#0.05) was achieved. All calculations were performed using the GraphPad Prism 6.0 program (GraphPad Software, La Jolla, CA). 
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